eFFECTOR Therapeutics (EFTR) Short Interest Ratio & Short Volume

Short interest is the volume of eFFECTOR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 687,000 shares of EFTR short. 16.84% of eFFECTOR Therapeutics' shares are currently sold short. Learn More on eFFECTOR Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EFTR shares currently have a short interest ratio of 1.0. Learn More on eFFECTOR Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.84% of eFFECTOR Therapeutics' floating shares are currently sold short.

eFFECTOR Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 687,000 shares, an increase of 650.0% from the previous total of 91,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

eFFECTOR Therapeutics currently has issued a total of 4,700,000 shares. Some of eFFECTOR Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. eFFECTOR Therapeutics currently has a public float of 4,080,000 shares.

16.84% of eFFECTOR Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to eFFECTOR Therapeutics: Alvotech (0.07%), LAVA Therapeutics (0.13%), Mainz Biomed (8.71%), Pharvaris (0.76%), Procaps Group S.A. (0.11%), and Mondee Holdings, Inc. (10.95%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.71 billion), TC Energy Co. ($2.95 billion), Moderna, Inc. ($2.63 billion), Royal Caribbean Cruises Ltd. ($2.53 billion), Paychex, Inc. ($2.03 billion), Cencora, Inc. ($2.03 billion), Tractor Supply ($1.91 billion), Rivian Automotive, Inc. ($1.78 billion), Chesapeake Energy Co. ($1.50 billion), and United Therapeutics Co. ($1.40 billion). View all of the most shorted stocks.

Short selling EFTR is an investing strategy that aims to generate trading profit from eFFECTOR Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for eFFECTOR Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EFTR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EFTR, twice per month. The most recent reporting period available is June, 30 2024.